University of Illinois at Chicago
Exemption #JDR448
Announcement of an Exempt Purchase
Award Info Published Friday February 21, 2025
Priority Healthcare/CuraScript SD Specialty DistrbLake Mary, FL
- Amount: An estimated $1,500,000
- Terms: An estimated start date of 7/1/2025 through 6/30/2028
- Renewals: None
Summary
Vendors
1 total
0 BEP vendors
0 VBP vendors
0 Small businesses
The University award process may be delayed as this award goes through a state approval process.
First published Friday, February 21, 2025
The University awarded a contract for restricted treatments.
This purchase is for restricted treatments that are not available from our primary contracted distributor and must be purchased from Curascript. These restricted treatments are Livdelzi and Ocaliva for primary biliary cholangitis, Lupkynis for lupus, and Tymlos for osteoporosis.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical at a university-operated health care center or dispensary that provides care, treatment, and medications for students, faculty and staff (30 ILCS 500 / 1-13(b-5)) These treatments are restricted and only available to highly accredited pharmacies such as the UI Health Specialty Pharmacy Services. Providing access to these treatments for UI Health patients provide the best outcomes for the patient.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire qualified veterans, minorities, females, persons with disabilities and ex-offenders.